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Excessive daytime sleepiness (EDS) and depression are com-
mon in Parkinson’s disease (PD) patients.1,2 EDS was reported 
in 20–50% of PD patients.1 However, the characteristics of EDS 
in PD are unclear. The risk factors for EDS are male gender, long 
disease duration, extent of motor symptoms severity, and do-
pamine agonist (DA) use.3 The effect of dopaminergic medica-
tion seems to be inconsistent. Generally, EDS appears to be cor-
related with higher doses of levodopa equivalents,1 but another 
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ABSTRACT
ObjectiveaaWe aimed to investigate the effect of ropinirole on excessive daytime sleepiness (EDS) and depression in Parkinson’s 
disease (PD) with a large population.
MethodsaaWe conducted a cross-sectional observational study at nine hospitals in Korea between April 24, 2013, and April 22, 
2015. We analyzed the demographic and clinical features, other medical history, history of antiparkinsonian medication within 6 
months, Hoehn and Yahr stage (HY stage), Unified Parkinson’s Disease Rating Scale (UPDRS) part II and III, Epworth Sleepiness 
Scale (ESS), and 30-item Geriatric Depression Scale (GDS-30).
ResultsaaFour-hundred-thirteen patients with PD (mean age: 65.2 ± 9.0 years; men: 227 patients) were analyzed. Multivariate 
logistic regression analysis showed that age at examination, UPDRS II, and GDS-30 were independent risk factors for EDS and 
that sex, UPDRS II, and ESS were independent risk factors for depression. 
ConclusionaaOur large group study did not find any significant associations of ropinirole with EDS and depression in Korean 
PD patients. 
Key WordsaaParkinson’s disease; ropinirole; levodopa; sleepiness; mood; excessive daytime sleepiness; depression.
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study showed that EDS is related to low doses of le-
vodopa and high doses of DA.4,5 Ropinirole, a DA, 
has also been suggested to be associated with EDS,6 
but there are conflicting results.7-11 
Clinically significant depressive symptoms have 
been reported in 35% of PD patients.2 Depression is 
common and even precedes the onset of motor man-
ifestation by many years.12 The serotonergic and/or 
noradrenergic system is known to be important in 
the pathogenesis of depression. In addition, the do-
paminergic system may also play a role in the devel-
opment of depression in PD.12 Depression is improved 
by dopaminergic medication, and depressive symp-
toms appear as medication wears off.12 It has been 
reported that ropinirole improves depressive symp-
toms,8,10 but there is still not enough evidence to sup-
port these findings.
Therefore, the aim of this study was to evaluate the 
effect of ropinirole on EDS and depression in PD pa-
tients. We also analyzed the effect of ropinirole on EDS 
through stratification of dopaminergic medication.
MATERIALS & METHODS
Study design
This was a cross-sectional observational study con-
ducted at nine hospitals in Korea between April 24, 
2013, and April 22, 2015. Participants were evaluat-
ed during one visit. We collected their demographic 
and clinical features, other medical history, history of 
antiparkinsonian medication within 6 months, Hoehn 
and Yahr stage (HY stage), and scores on the Unified 
Parkinson’s Disease Rating Scale (UPDRS) part II 
and III, Epworth Sleepiness Scale (ESS), and 30-item 
Geriatric Depression Scale (GDS-30). Patients with 
an ESS score > 10 were classified as having EDS. Pa-
tients with GDS-30 > 17 were classified as having 
depression. Levodopa equivalent daily doses (LEDD) 
were calculated according to the usual formula.13
Patients
The inclusion criteria were 1) diagnosis of idio-
pathic PD as defined by the UK Parkinson’s Disease 
Society Brain Bank Criteria;14 2) patients who had 
taken antiparkinsonian medications, including ro-
pinirole and levodopa, for more than six months at 
the time of enrollment; and 3) no changes of the doses 
of ropinirole and levodopa for more than one month 
at the time of enrollment. The exclusion criteria were 
1) Alzheimer’s dementia and Vascular dementia, 
clinically diagnosed using the Diagnostic and Statis-
tical Manual of Mental Disorders diagnostic criteria; 
2) patients who participated in other clinical trials at 
the time of enrollment; 3) chronic use of a sedative; 
4) history of alcohol abuse; 5) severe comorbid dis-
orders that can affect sleep (i.e., chronic obstructive 
pulmonary disease, ischemic heart disease, stroke, 
and painful joint disease, etc.); and 6) having taken 
pramipexole or other DAs (rotigotine, bromocrip-
tine) within six months of the time of enrollment. 
Standard protocol approvals, registrations, 
and patient consents
The study was conducted in accordance with the 
Declaration of Helsinki and Good Clinical Practice 
Guidelines. This study protocol was approved by the 
Institutional Review Board of all nine centers (IRB 
No. 2013-007). All participants provided written, in-
formed consent prior to enrollment.
Statistical analysis
Data are expressed as the means ± standard devi-
ation. Measurements were compared between pa-
tients with EDS and without EDS. Measurements 
were compared between patients with depression 
and without depression. For univariate analysis, we 
used the independent t-test and chi-square test. Mul-
tivariate logistic regression with the use of backward 
elimination was performed on variables that were 
associated with p < 0.20 according to univariate lo-
gistic regression. We chose p = 0.20 as the threshold 
of significance in multivariate analysis as suggested 
elsewhere as an appropriate threshold.15 Because the 
ranges of the total LEDD were very wide, we thought 
that it might be a bias for the comparison. Therefore, 
we classified patients into three groups according to 
the total LEDD, less than the 32nd percentile; 33rd to 
66th percentile; and greater that the 67th percentile, 
and compared the dosage of ropinirole between pa-
tients without and with EDS in each group. All sta-
tistical analyses were performed using SAS Proprie-
tary Software 9.4 (SAS Institute, Inc., Cary, NC, USA). 
Values of p < 0.05 were regarded as significant.
RESULTS
Four-hundred-thirteen of 426 patients who pro-
vided informed consent were enrolled. Thirteen 
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patients were excluded; 12 patients did not meet the 
inclusion criteria, and the other patient’s ESS was 
missing. The demographic and clinical features are 
summarized in Table 1. 
Comparison between patients without and 
with EDS
Patients with EDS were more likely to be men, had 
higher UPDRS II & III scores, have more frequent 
motor fluctuation and dyskinesia, and have more 
severe depression. There was a significant difference 
in the laterality of motor symptoms at the time of 
evaluation. In patients with EDS, the larger propor-
tion of lateralized motor symptoms occurred on the 
left side. There was no significant difference of the 
total LEDD between patients without EDS and with 
EDS. Moreover, there was no significant difference 
of the levodopa and ropinirole doses (Table 2). 
 Multivariate logistic regression analysis revealed 
that age at examination, UPDRS II, and depression 
were independent risk factors for EDS. Total LEDD, 
levodopa and ropinirole doses were not associated 
with EDS (Table 3).
Comparison between patients without and 
with depression
Patients with depression were more likely to be 
women; had a higher HY stage as well as UPDRS II 
and UPDRS III scores; had more severe ESS; and 
had a higher GDS-30 score. Total LEDD, levodopa 
dose, and ropinirole dose were not different between 
patients without and with depression (Table 4). 
Multivariate logistic regression analysis showed 
that sex, UPDRS II, and ESS were independently as-
sociated with depression. Total LEDD, levodopa 
dose, and ropinirole dose were not significant risk 
factors (Table 5).
Comparison of the ropinirole dose between 
patients without and with EDS after total 
LEDD stratification
Four-hundred-thirteen patients were divided into 
three groups according to the percentiles of total LEDD. 
There were larger doses of ropinirole in patients with 
EDS than in patients without EDS in the lowest 33rd 
percentile group (p = 0.009). In the other groups, the 
ropinirole dose was not significantly different between 
patients without and with EDS (Table 6).
Table 1. Demographics and clinical features of 413 patients 
with Parkinson’s disease
Variables Patients (n = 413)
Age, years 65.2 ± 9.0
Men, n (%) 227 (55.0)
HY stage* 2.2 ± 0.7
UPDRS II† 8.6 ± 5.8
UPDRS III‡ 19.8 ± 10.7
Motor fluctuation, n (%) 108 (26.2)
Dyskinesia, n (%) 143 (34.6)
ESS 8.4 ± 5.4
GDS-30§ 11.9 ± 7.3
Lateralityǁ, n (%)
Right 153 (37.5)
Left 127 (31.1)
Symmetric 128 (31.4)
Total LEDD 829.5 ± 388.2
Levodopa 488.1 ± 261.3
Ropinirole¶ 8.4 ± 5.5
*data missing from two patients, †data missing from seven pa-
tients,  ‡data missing from one patient, §data missing from six 
patients, ǁdata missing from five patients, ¶the mean value of ro-
pinirole is presented as LEDD. HY stage: Hoehn and Yahr stage, 
UPDRS: Unified Parkinson’s Disease Rating Scale, ESS: Ep-
worth Sleepiness Scale, GDS-30: 30-item Geriatric Depression 
Scale, LEDD: levodopa equivalent daily dose.
Table 2. Comparison of Parkinson’s disease patients with-
out and with EDS
Variables
Without EDS
(n = 288) 
With EDS
(n = 125)
p value
Age, years 65.7 ± 8.9 64.1 ± 9.1 0.1167
Men, n (%) 147 (51.0) 80 (64.0) 0.0150
HY stage* 2.2 ± 0.7 2.3 ± 0.8 0.1935
UPDRS II† 7.6 ± 5.2 11.0 ± 6.6 < 0.0001
UPDRS III‡ 18.9 ± 10.4 21.9 ± 11.2 0.0080
Motor fluctuation, 
n (%)
60 (20.8) 48 (38.4) 0.0002
Dyskinesia, n (%) 90 (31.3) 53 (42.4) 0.0287
ESS 5.5 ± 2.8 15.1 ± 3.7 < 0.0001
GDS-30§ 11.1 ± 7.0 13.7 ± 7.8 0.0020
Lateralityǁ, n (%) 0.0024
Right 106 (37.1) 47 (38.5)
Left 77 (26.9) 50 (41.0)
Symmetric 103 (36.0) 25 (20.5)
Total LEDD 829.2 ± 378.7 853.3 ± 390.7 0.4060
Levodopa 481.2 ± 254.6 504.0 ± 276.5 0.4150
Ropinirole¶ 8.2 ± 5.7 8.9 ± 4.9 0.2240
*data missing from two patients (one patient without EDS, the 
other with EDS), †data missing from seven patients (six without 
EDS, the other with EDS),  ‡data missing from one in patients 
without EDS, §data missing from six patients (three without 
EDS, the other with EDS), ǁdata missing from five patients (two 
without EDS, the other with EDS), ¶the mean value of ropinirole 
is presented as LEDD. EDS: excessive daytime sleepiness, 
HY stage: Hoehn and Yahr stage, UPDRS: Unified Parkinson’s 
Disease Rating Scale, ESS: Epworth Sleepiness Scale, GDS-
30: 30-item Geriatric Depression Scale, LEDD: levodopa 
equivalent daily dose.
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DISCUSSION
This observational study did not find any influ-
ence of ropinirole on EDS and depression in Korean 
PD patients. Younger age at visit, lower activities of 
daily life (ADL), and depression were independent 
risk factors for EDS. Women, lower ADL and EDS 
were independent risk factors for depression.
The relationship between DAs and EDS has been 
controversial. In 1999, sleep attacks of ropinirole and 
pramipexole were first introduced,16 but later, other 
studies showed that there was no difference among 
DAs where EDS was concerned.6,17 It was suggested 
that total LEDD, rather than specific DAs, might be 
more important in the pathogenesis of EDS.6 The 
opposite results were also reported. There was no 
correlation found between total LEDD and EDS, and 
a higher levodopa dose was associated with greater 
vigilance.18 In our study, the total LEDD, levodopa 
dose, and ropinirole dose were not associated with 
EDS. We do not know the exact reason why these re-
sults are contradictory. Heterogeneous populations 
among studies might be a reason. A variety of clini-
cal features may affect EDS in PD. In addition to DA 
Table 3. Excessive daytime sleepiness; univariate and multivariate logistic regression analyses
Variables
Univariate Multivariate
p value OR 95% CI p value OR 95% CI
Age 0.1173 0.982 0.959‒1.005 0.025 1.735 1.072‒2.810
Sex (men) 0.0155 1.705 1.107‒2.627
HY stage 0.1680 1.238 0.914‒1.679
UPDRS II < 0.0001 1.105 1.063‒1.149 0.002 1.070 1.025‒1.117
UPDRS III 0.0090 1.026 1.006‒1.046
Motor fluctuation 0.0002 2.369 1.497‒3.749 0.055 1.657 0.989‒2.777
Dyskinesia 0.0293 1.619 1.050‒2.498
GDS-30 0.0020 1.048 1.018‒1.079 0.022 1.041 1.006‒1.078
Laterality 0.051 0.553 0.306‒1.002
Left 0.1306 1.464 0.893‒2.402
Symmetric 0.0336 0.547 0.314‒0.954
Total LEDD 0.4050 1.000 1.000‒1.001
Levodopa 0.4150 1.000 1.000‒1.001
Ropinirole 0.2250 1.023 0.986‒1.063
HY stage: Hoehn and Yahr stage, UPDRS: Unified Parkinson’s Disease Rating Scale, GDS-30: 30-item Geriatric Depression 
Scale, LEDD: levodopa equivalent daily dose, OR: odds ratio, CI: confidence interval.
Table 4. Comparison of Parkinson’s disease patients without and with depression
Variables Without depression (n = 310) With depression (n = 97) p value
Age, years 65.1 ± 9.0 65.6 ± 9.3 0.6280
Men, n (%) 180 (58.1) 42 (43.3) 0.0110
HY stage* 2.2 ± 0.7 2.4 ± 0.7 0.0170
UPDRS II† 7.6 ± 4.9 11.8 ± 7.1 < 0.0001
UPDRS III‡ 19.1 ± 10.6 22.1 ± 11.2 0.0160
Motor fluctuation, n (%) 77 (24.8) 29 (29.9) 0.3220
Dyskinesia, n (%) 102 (32.9) 39 (40.2) 0.1870
ESS 7.7 ± 5.2 10.6 ± 5.6 < 0.0001
GDS-30 8.6 ± 4.7 22.4 ± 2.9 < 0.0001
Laterality§, n (%) 0.4520
Right 119 (38.8) 33 (34.7)
Left 96 (31.3) 27 (28.4)
Symmetric 92 (30.0) 35 (36.8)
Total LEDD 820.8 ± 392.1 847.7 ± 356.7 0.5460
Levodopa 482.6 ± 266.6 493.6 ± 246.2 0.7190
Ropiniroleǁ 8.4 ± 5.4 8.7 ± 6.0 0.5860
*data missing from one patient with depression, †data missing from seven patients (one without depression, the other with depres-
sion),  ‡data missing from one in patients without depression, §data missing from five patients (three without depression, the other 
with depression), ǁthe mean value of ropinirole is presented as LEDD. HY stage: Hoehn and Yahr stage, UPDRS: Unified Parkin-
son’s Disease Rating Scale, ESS: Epworth Sleepiness Scale, GDS-30: 30-item Geriatric Depression Scale, LEDD: levodopa 
equivalent daily dose.
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use, age, gender, disease severity, poor nighttime 
sleep, cognition, hallucination, dyskinesia, antihy-
pertensive medications, body mass index, and pain 
are associated with higher EDS.19-21 In our study, 
younger age, poorer ADL, and higher GDS-30 were 
associated with higher EDS. It is not clear whether 
depression is a risk factor. In our study, depression 
was a risk factor for EDS, but other studies reached 
inconsistent conclusion. One study reported that de-
pression was correlated with severe EDS,22 but an-
other study reported that depression was correlated 
with less EDS.23 A different study showed that there 
was no association between depression and EDS.24 
Another possible reason was suggested: a non-do-
paminergic system might be more responsible for 
EDS.22 In an animal study, dopamine and serotonin 
played roles in the regulation of sleep and waking.25 
Therefore, studies with more comprehensive clini-
cal features (i.e., fatigue) are needed to understand 
EDS.22,26 
One possible interesting finding of our study is 
that patients who displayed EDS had taken a larger 
dose of ropinirole in the lowest 33rd percentile group 
of total LEDD (Table 6). Considering that most pa-
tients in the lowest 33rd percentile group of total 
LEDD may be early PD, this observation suggests 
that close attention might be needed when starting 
ropinirole in early PD.
We did not find any effect of dopaminergic med-
ication on depression. Only gender, ADL and EDS 
were risk factors for depression in PD. DAs may al-
leviate depressive symptoms in PD.10,27-29 Pramipex-
ole is known to have a direct antidepressant effect.27 
It seems that there is not sufficient evidence for the 
effect of ropinirole, although it has been shown to 
lead to some improvement of depression in various 
disorders, including PD.10,30,31 In our study, there was 
no difference of the ropinirole dose between patients 
without and with depression. One possible explana-
tion why ropinirole did not show a clear effect, un-
like pramipexole, is the difference of the binding af-
finities for the D3 receptor among DAs.32 Ropinirole 
and pramipexole are D2/D3 DAs, but pramipexole 
has a higher affinity for D3 receptors than ropini-
role.32 The D3 receptor is the major dopamine recep-
tor of the mesolimbic system,29 which may be associ-
ated with behavior and mood.32
The risk factors for depression in PD have been re-
Table 5. Depression, univariate and multivariate logistic regression analysis
Variables
Univariate Multivariate
p value OR 95% CI p value OR 95% CI
Age 0.6270 1.006 0.981‒1.032
Sex (men) 0.0110 0.552 0.348‒0.874 0.0003 0.383 0.228‒0.644
HY stage 0.0180 1.489 1.071‒2.071
UPDRS II < 0.0001 1.133 1.085‒1.183 < 0.0001 1.129 1.079‒1.182
UPDRS III 0.0170 1.026 1.005‒1.047
Motor fluctuation 0.3230 1.290 0.779‒2.139
Dyskinesia 0.1880 1.371 0.857‒2.194
ESS < 0.0001 1.099 1.054‒1.145 0.0002 1.092 1.043‒1.143
Laterality
Left 0.9620 1.014 0.571‒1.803
Symmetric 0.2580 1.372 0.793‒2.373
Total LEDD 0.5460 1.000 1.000‒1.001
Levodopa 0.7180 1.000 0.999‒1.001
Ropinirole 0.5850 1.011 0.971‒1.053
HY stage: Hoehn and Yahr stage, UPDRS: Unified Parkinson’s Disease Rating Scale, ESS: Epworth Sleepiness Scale, LEDD: le-
vodopa equivalent daily dose, OR: odds ratio, CI: confidence interval.
Table 6. Comparison of the ropinirole dose between Parkin-
son’s disease without and with EDS (following total LEDD 
stratification*)
Without EDS  
(n = 288)
With EDS  
(n = 125)
p value
Group 1 0.009
Cases 96 41
Ropinirole (mg/d) 5.5 ± 3.4 7.2 ± 3.8
Group 2 0.343
Cases 102 36
Ropinirole (mg/d) 8.0 ± 5.2 8.9 ± 5.0
Group 3 0.357
Cases 90 48
Ropinirole (mg/d) 11.4 ± 6.5 10.4 ± 5.2
*groups were divided into three percentile categories of total 
LEDD: group 1 (n = 137, 487.2 ± 127.3 mg/d); group 2 (n = 138, 
845.3 ± 109.6 mg/d); group 3 (n = 138, 1510.5 ± 444.9 mg/d). 
EDS: excessive daytime sleepiness, LEDD: levodopa equiva-
lent daily dose.
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ported to be severe motor symptoms, disease dura-
tion, advanced disease stage, poor ADL, high LEDD, 
hallucination, sleep disturbance, dysautonomia, and 
dementia.33,34 Our univariate analysis results showed 
that there were several different factors, including 
advanced disease stage and severe motor symptoms, 
between patients without depression and with de-
pression, but in the multivariate analysis, the inde-
pendent risk factors were women, lower ADL, and 
higher ESS. This is noteworthy for EDS. Previous 
studies have reported that sleep disturbances might 
be a risk factor for depression, but they did not check 
EDS.35,36 
Our study has some limitations. First, this was an 
observational study. We could not determine the ef-
fect of ropinirole alone on EDS and depression be-
cause enrolled patients had taken combined anti-
parkinsonian medications that included ropinirole 
and levodopa. Second, the demographics between 
PD patients without and with EDS were not matched. 
Although we adjusted these variables with multivar-
iate logistic regression, these differences might be 
biased. Third, another sleep problem (i.e., REM sleep 
behavior disorder, insomnia) may affect EDS, but we 
did not check for other sleep problems.
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